Sonnet BioTherapeutics Stock (NASDAQ: SONN) stock price, news, charts, stock research, profile.
Open | $1.660 |
Close | $1.570 |
Volume / Avg. | 25.948K / 96.945K |
Day Range | 1.500 - 1.660 |
52 Wk Range | 1.080 - 26.400 |
Market Cap | $5.167M |
P/E Ratio | 0.580 |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 43 |
Short Interest | 13.49% |
Days to Cover | 23.67 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Sonnet BioTherapeutics (NASDAQ: SONN) through any online brokerage.
Other companies in Sonnet BioTherapeutics’s space includes: Alzamend Neuro (NASDAQ:ALZN), Virios Therapeutics (NASDAQ:VIRI), Tharimmune (NASDAQ:THAR), Synaptogenix (NASDAQ:SNPX) and Geovax Labs (NASDAQ:GOVX).
The latest price target for Sonnet BioTherapeutics (NASDAQ: SONN) was reported by Chardan Capital on Tuesday, May 28, 2024. The analyst firm set a price target for 30.00 expecting SONN to rise to within 12 months (a possible 1707.23% upside). 7 analyst firms have reported ratings in the last year.
The stock price for Sonnet BioTherapeutics (NASDAQ: SONN) is $1.66 last updated May 30, 2024 at 5:50 PM EDT.
There are no upcoming dividends for Sonnet BioTherapeutics.
Sonnet BioTherapeutics’s Q3 earnings are confirmed for Monday, August 12, 2024.
There is no upcoming split for Sonnet BioTherapeutics.
Sonnet BioTherapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.